Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer

被引：0
|
作者：
Lisha Wang
Fei Ren
Qifeng Wang
Lee Ann Baldridge
M. Francesca Monn
Kurt W. Fisher
Weiqi Sheng
Xiaoyan Zhou
Xiang Du
Liang Cheng
机构：
[1] Fudan University Shanghai Cancer Center,Department of Pathology
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] University of Michigan,Michigan Center for Translational Pathology
[4] Indiana University School of Medicine,Department of Pathology and Laboratory Medicine
来源：
Molecular Diagnosis & Therapy | 2016年 / 20卷
关键词：
Colorectal Cancer Patient; Immune Checkpoint; Multiple Cancer Type; Patient Clinical Outcome; Immunosuppressive Tumor Microenvironment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 181
页数：6
相关论文
共 50 条
  • [41] Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer
    Capizzi, Elisa
    Ricci, Costantino
    Giunchi, Francesca
    Zagnoni, Stefano
    Ceccarelli, Claudio
    Gomez, Begona Urrios Alvarez
    Casolari, Laura
    Gelsomino, Francesco
    Trisolini, Rocco
    Fiorentino, Michelangelo
    Ardizzoni, Andrea
    LUNG CANCER, 2018, 126 : 9 - 14
  • [42] Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
    Muenst, S.
    Schaerli, A. R.
    Gao, F.
    Daester, S.
    Trella, E.
    Droeser, R. A.
    Muraro, M. G.
    Zajac, P.
    Zanetti, R.
    Gillanders, W. E.
    Weber, W. P.
    Soysal, S. D.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 15 - 24
  • [43] Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
    S. Muenst
    A. R. Schaerli
    F. Gao
    S. Däster
    E. Trella
    R. A. Droeser
    M. G. Muraro
    P. Zajac
    R. Zanetti
    W. E. Gillanders
    W. P. Weber
    S. D. Soysal
    Breast Cancer Research and Treatment, 2014, 146 : 15 - 24
  • [44] Molecular Mutations and Clinical Features That Affect Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Mesothelioma
    Kwon, Jung Woo
    Chen-Yost, Heather
    Tjota, Melissa
    Segal, Jeremy
    Mueller, Jeffrey
    Husain, Aliya
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1634 - S1636
  • [45] Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression
    Pyo, Jung-Soo
    Ko, Soo Hee
    Ko, Young San
    Kim, Nae Yu
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (02)
  • [46] Expression of programmed death ligand 1 (PD-L1) in malignant and nonmalignant pancreatic tissue
    Razzaque, Saqib
    Ashraf, Noman
    Chavez, Julio C.
    Malafa, Mokenge Peter
    Coppola, Domenico
    Springett, Gregory M.
    Helm, James
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] Programmed Cell Death Ligand 1 (PD-L1) Expression in Pancreatic Ductal Adenocarcinoma
    Sheffield, Brandon S.
    Kalloger, Steve E.
    Milne, Katy
    Nelson, Brad H.
    Renouf, Daniel
    Schaeffer, David F.
    MODERN PATHOLOGY, 2016, 29 : 200A - 200A
  • [48] Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
    Kowalski, Andrzej
    Malinowska, Katarzyna
    Olszewski, Jurek
    Zielinska-Blizniewska, Hanna
    BIOMOLECULES, 2021, 11 (07)
  • [49] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [50] Programmed Death-Ligand 1 (PD-L1) Expression in Pheochromocytoma: Clinicopathologic Correlation
    Xiong, Meng-Jun
    Kissick, Haydn
    Master, Viraj
    Osunkoya, Adeboye O.
    MODERN PATHOLOGY, 2019, 32
12345